Severe and continuous immunoparesis during induction or maintenance therapy in nontransplant patients with multiple myeloma is a sign of poor prognosis
Objective Multiple myeloma (MM) varies in clinical behavior, response to treatment and prognosis due to the heterogeneity of the disease. Data on the association between the immunoparesis status during treatment and prognosis in nontransplant MM patients are limited.Methods In a retrospective analys...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Hematology |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/16078454.2024.2329378 |
| _version_ | 1826936809823666176 |
|---|---|
| author | Ying Chen Zhe Chen Junjie Cao Li Lin Jipeng Li |
| author_facet | Ying Chen Zhe Chen Junjie Cao Li Lin Jipeng Li |
| author_sort | Ying Chen |
| collection | DOAJ |
| description | Objective Multiple myeloma (MM) varies in clinical behavior, response to treatment and prognosis due to the heterogeneity of the disease. Data on the association between the immunoparesis status during treatment and prognosis in nontransplant MM patients are limited.Methods In a retrospective analysis of 142 patients with MM, we examined the relationship between immunoparesis status and prognosis during treatment. All patients received novel agent-based therapy and did not undergo autologous stem cell transplantation. One, two, or three uninvolved immunoglobulins (Igs) below the lowest thresholds of normalcy were used to identify immunoparesis.Results Patients with a greater degree of immunoparesis during treatment had shorter progression-free survival (PFS) and overall survival (OS). A total of 46.5% of the patients had severe and continuous immunoparesis (at least two uninvolved Igs suppressed continuously during treatment), representing a worse prognosis than those with complete or partial normalization of Igs during treatment. Among patients who achieved at least complete remission, PFS was poor in patients with severe and continuous immunoparesis. Furthermore, severe and continuous immunoparesis during treatment was a poor prognostic factor for PFS and OS according to multivariate analyses.Conclusion The degree of immunoparesis during treatment is a follow-up indicator for survival in nontransplant myeloma patients, and severe and continuous immunoparesis in nontransplant myeloma patients might be a sign of poor prognosis. |
| first_indexed | 2024-04-25T00:38:04Z |
| format | Article |
| id | doaj.art-dfe0be497cb54bc6bb9da98c61c3a593 |
| institution | Directory Open Access Journal |
| issn | 1607-8454 |
| language | English |
| last_indexed | 2025-02-17T18:28:26Z |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Hematology |
| spelling | doaj.art-dfe0be497cb54bc6bb9da98c61c3a5932024-12-12T15:08:52ZengTaylor & Francis GroupHematology1607-84542024-12-0129110.1080/16078454.2024.2329378Severe and continuous immunoparesis during induction or maintenance therapy in nontransplant patients with multiple myeloma is a sign of poor prognosisYing Chen0Zhe Chen1Junjie Cao2Li Lin3Jipeng Li4Department of Central Laboratory, The Affiliated People’s Hospital of Ningbo University, Ningbo, People’s Republic of ChinaDepartment of Central Laboratory, The Affiliated People’s Hospital of Ningbo University, Ningbo, People’s Republic of ChinaDepartment of Hematology, The Affiliated People’s Hospital of Ningbo University, Ningbo, People’s Republic of ChinaDepartment of Hematology, The Affiliated People’s Hospital of Ningbo University, Ningbo, People’s Republic of ChinaDepartment of Central Laboratory, The Affiliated People’s Hospital of Ningbo University, Ningbo, People’s Republic of ChinaObjective Multiple myeloma (MM) varies in clinical behavior, response to treatment and prognosis due to the heterogeneity of the disease. Data on the association between the immunoparesis status during treatment and prognosis in nontransplant MM patients are limited.Methods In a retrospective analysis of 142 patients with MM, we examined the relationship between immunoparesis status and prognosis during treatment. All patients received novel agent-based therapy and did not undergo autologous stem cell transplantation. One, two, or three uninvolved immunoglobulins (Igs) below the lowest thresholds of normalcy were used to identify immunoparesis.Results Patients with a greater degree of immunoparesis during treatment had shorter progression-free survival (PFS) and overall survival (OS). A total of 46.5% of the patients had severe and continuous immunoparesis (at least two uninvolved Igs suppressed continuously during treatment), representing a worse prognosis than those with complete or partial normalization of Igs during treatment. Among patients who achieved at least complete remission, PFS was poor in patients with severe and continuous immunoparesis. Furthermore, severe and continuous immunoparesis during treatment was a poor prognostic factor for PFS and OS according to multivariate analyses.Conclusion The degree of immunoparesis during treatment is a follow-up indicator for survival in nontransplant myeloma patients, and severe and continuous immunoparesis in nontransplant myeloma patients might be a sign of poor prognosis.https://www.tandfonline.com/doi/10.1080/16078454.2024.2329378severe and continuous immunoparesismultiple myelomatreatmentsurvivalresponse |
| spellingShingle | Ying Chen Zhe Chen Junjie Cao Li Lin Jipeng Li Severe and continuous immunoparesis during induction or maintenance therapy in nontransplant patients with multiple myeloma is a sign of poor prognosis Hematology severe and continuous immunoparesis multiple myeloma treatment survival response |
| title | Severe and continuous immunoparesis during induction or maintenance therapy in nontransplant patients with multiple myeloma is a sign of poor prognosis |
| title_full | Severe and continuous immunoparesis during induction or maintenance therapy in nontransplant patients with multiple myeloma is a sign of poor prognosis |
| title_fullStr | Severe and continuous immunoparesis during induction or maintenance therapy in nontransplant patients with multiple myeloma is a sign of poor prognosis |
| title_full_unstemmed | Severe and continuous immunoparesis during induction or maintenance therapy in nontransplant patients with multiple myeloma is a sign of poor prognosis |
| title_short | Severe and continuous immunoparesis during induction or maintenance therapy in nontransplant patients with multiple myeloma is a sign of poor prognosis |
| title_sort | severe and continuous immunoparesis during induction or maintenance therapy in nontransplant patients with multiple myeloma is a sign of poor prognosis |
| topic | severe and continuous immunoparesis multiple myeloma treatment survival response |
| url | https://www.tandfonline.com/doi/10.1080/16078454.2024.2329378 |
| work_keys_str_mv | AT yingchen severeandcontinuousimmunoparesisduringinductionormaintenancetherapyinnontransplantpatientswithmultiplemyelomaisasignofpoorprognosis AT zhechen severeandcontinuousimmunoparesisduringinductionormaintenancetherapyinnontransplantpatientswithmultiplemyelomaisasignofpoorprognosis AT junjiecao severeandcontinuousimmunoparesisduringinductionormaintenancetherapyinnontransplantpatientswithmultiplemyelomaisasignofpoorprognosis AT lilin severeandcontinuousimmunoparesisduringinductionormaintenancetherapyinnontransplantpatientswithmultiplemyelomaisasignofpoorprognosis AT jipengli severeandcontinuousimmunoparesisduringinductionormaintenancetherapyinnontransplantpatientswithmultiplemyelomaisasignofpoorprognosis |